Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide

Eur J Haematol. 2013 Feb;90(2):162-3. doi: 10.1111/ejh.12053. Epub 2013 Jan 7.

Abstract

The prognosis of therapy refractory angioimmunoblastic lymphoma (AITL) is very poor. In this report we describe a patient with AITL refractory to 2 lines of chemotherapy. He was treated with lenalidomide 15 mg continuously and prednisone. After 2 yr follow-up, the patient has no detectable disease. Lenalidomide was well tolerated without side-effects. Lenalidomide even in lower dosed combined with steroids can induce complete responses in patients with refractory AITL.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Hormonal / administration & dosage*
  • Humans
  • Immunoblastic Lymphadenopathy / drug therapy*
  • Immunoblastic Lymphadenopathy / pathology
  • Lenalidomide
  • Lymphoma, T-Cell / drug therapy*
  • Lymphoma, T-Cell / pathology
  • Male
  • Middle Aged
  • Prednisone / administration & dosage*
  • Remission Induction
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives*

Substances

  • Antineoplastic Agents, Hormonal
  • Thalidomide
  • Lenalidomide
  • Prednisone